Company intelligence / Profile preview

AAV GTx

Ownership: Private
Development stage: Preclinical

Overview

Gritgen Therapeutics is a clinical-stage biotech company focused on developing adeno-associated virus (AAV) gene therapies. The company has established two proprietary AAV gene therapy technology platforms. Specific clinical results are not detailed in the provided information[10].

"Gritgen Therapeutics is a clinical-stage AAV GTx-focused biotech. We have establised two propreitary AAV GTx technology platforms..."[10]

Therapeutic areas: Rare Diseases
Modalities: Gene therapyAAV gene therapy (Adeno-associated virus gene therapy)
Industry: Biotech

Beyond the preview

Go deeper on AAV GTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV GTx.

Explore the full profile